Home・Aandelen Lijst・CytoSorbents Corp

CytoSorbents Corp

Gesloten

SectorGezondheidszorg

0.34 -8.11

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.36

Max

0.37

Belangrijke statistieken
By Trading Economics
Inkomsten	-4.4M -9.5M
Verkoop	769K 9.6M
EPS	-0.07
Winstmarge	-99.107
Werknemers	129
EBITDA	547K -3.3M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+102.7% upside

Dividenden
By Acuity
Volgende Winsten	12 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	572K 24M
Vorige openingsprijs	8.45
Vorige sluitingsprijs	0.34

Nieuwssentiment

By Acuity

50%

147 / 340 Rangschikking in Healthcare

CytoSorbents Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 aug 2026, 20:01 UTC

Cytosorbents Corp shares are higher today, continuing a strong upward trend since Thursday's close amid positive market sentiment and related equity gains.

20 aug 2026, 23:01 UTC

Cytosorbents Corp shares are lower in after-market hours, continuing a decline amid broader market pressure from disappointing sales growth at Walmart Inc.

18 aug 2026, 20:06 UTC

Cytosorbents Corp shares are lower today, continuing a downward trend amid rising U.S. Treasury yields and persistent inflation concerns. No specific news was identified.

17 aug 2026, 19:36 UTC

Cytosorbents Corp shares are lower today amid rising Treasury yields and inflation concerns. The stock remains above its 20-day moving average.

14 aug 2026, 20:06 UTC

Cytosorbents Corp shares are higher today, continuing a notable upward trend despite mixed market sentiment and no specific company news identified.

13 aug 2026, 19:16 UTC

Cytosorbents Corp shares are higher today, reflecting routine performance and buoyed by overall market sentiment, despite no specific news driving the movement.

12 aug 2026, 19:46 UTC

Cytosorbents Corp is trading higher, building on gains since Tuesday's close. Broader market sentiment is positive amid favorable inflation data and strong tech earnings.

11 aug 2026, 22:01 UTC

Cytosorbents Corp shares are higher in after-market trading, following notable activity after the market closed, despite no specific company news identified.

10 aug 2026, 19:21 UTC

News

Cytosorbents Corp shares are higher, driven by gains in the Health Care Equipment sector. The company reported Q2 revenue of $9.63 million, exceeding forecasts.

7 aug 2026, 20:51 UTC

Cytosorbents Corp shares declined in after-hours trading, continuing lower since Friday's close, with no specific news identified to explain the movement.

6 aug 2026, 19:16 UTC

Cytosorbents Corp shares are higher during Thursday's session, continuing a strong upward trend since Wednesday's close, with no specific news identified for the increase.

5 aug 2026, 22:06 UTC

Cytosorbents Corp shares are higher in after-market trading, reaching a high of 2.63% following an initial dip. The stock remains above its 20-day moving average.

4 aug 2026, 21:01 UTC

Cytosorbents Corp shares are higher in after-market trading amid positive market sentiment linked to U.S.-Iran negotiations and declining crude oil prices.

3 aug 2026, 19:56 UTC

Cytosorbents Corp shares are higher during Monday's session, tracking a broader market uptick despite being below the 20-day moving average.

31 jul 2026, 20:06 UTC

Cytosorbents Corp. shares are trading roughly flat amid no specific news. The broader market also closed near unchanged since Thursday.

29 jul 2026, 20:08 UTC

Cytosorbents Corp shares are lower today, following an early peak and trading below the 20-day moving average. No specific news was identified for the decline.

28 jul 2026, 18:46 UTC

Cytosorbents Corp is trading higher during Tuesday's session, recovering from an earlier dip. No specific news was identified to explain the movement.

27 jul 2026, 18:41 UTC

Cytosorbents Corp shares are lower today amid notable volatility, with no specific news identified to explain the decline during Monday's session.

24 jul 2026, 19:06 UTC

Cytosorbents Corp shares are lower, marking three consecutive daily declines amid a broader market pullback influenced by falling crude oil prices.

22 jul 2026, 20:13 UTC

Cytosorbents Corp shares are lower in after-market hours amid rising crude oil prices and escalating U.S.-Iran tensions. The stock remains below its 20-day moving average.

21 jul 2026, 18:31 UTC

Cytosorbents Corp shares are higher today, reflecting broader market optimism despite earlier fluctuations. Strong buying in technology stocks supports this upward movement.

20 jul 2026, 19:16 UTC

News

Cytosorbents plans to report second-quarter 2026 results on August 6. The company is also pursuing FDA and Health Canada approval for its DrugSorb®-ATR device.

Peer Vergelijking

Prijswijziging

CytoSorbents Corp Prognose

Koersdoel

By TipRanks

102.7% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 0.75 USD 102.7%

Hoogste 0.75 USD

Laagste 0.75 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor CytoSorbents Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan CytoSorbents Corp - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

147 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.